RYTVEL Biotech

RYTVEL Biotech is focusing on developing drugs to turn off inflammation using small peptides exhibiting allosteric properties targeting major pro-inflammatory receptors like interleukin 1R.

The lead product, Rytvela (a selective antagonist of the IL-1 receptor) has strong anti-inflammatory property and is currently developed for the treatment of the cause and ensuing serious consequences of preterm birth.


RYTVEL’s mission is to prevent and cure inflammation by developing first-in-class therapeutic solutions.


RYTVEL Biotech will be the first company exploring a new paradigm therapy to develop Rytvela, an effective drug to end preterm birth to the benefit of women and newborns.